Merck & Co., Inc. is 185.3x more valuable than AbCellera Biologics Inc. by market capitalization ($298.26 B vs $1.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABCL | MRK |
|---|---|---|
| Market cap | $1.61 B | $298.26 B |
| US-listed rank | #2274 | #45 |
| Revenue (latest FY) | $75.13M | $65.01B |
| Net income (latest FY) | -$146.41M | $18.25B |
| Net margin | -194.9% | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 297 | 996 |
Merck & Co., Inc. is 185.3x more valuable than AbCellera Biologics Inc. by market capitalization ($298.26 B vs $1.61 B).
In their latest fiscal years, AbCellera Biologics Inc. reported $75.13M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: AbCellera Biologics Inc. and Merck & Co., Inc., or browse the full rankings.